Description

Lobradimil, also known as RMP-7, is a synthetic bradykinin analog peptide that acts as a potent and selective bradykinin B2 receptor agonist. It increases the permeability of the blood-brain barrier (BBB), facilitating the delivery of therapeutic agents to the brain. Lobradimil is utilized in laboratory research to study BBB modulation and its potential applications in brain tumor therapies. It is manufactured under GMP standards, ensuring high purity and consistency. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Lobradimil is a synthetic bradykinin analog that, upon binding to bradykinin B2 receptors on brain capillary endothelial cells, transiently increases the permeability of the blood-brain barrier. This effect facilitates the delivery of hydrophilic therapeutic agents to the brain. Lobradimil is primarily used in laboratory research to study BBB modulation and its potential applications in enhancing the delivery of chemotherapeutic agents to brain tumors. For laboratory research use only.

Side Effects (For Reference Only in Models)

In laboratory models, Lobradimil may induce transient hypotension, flushing, headache, and gastrointestinal complaints. These effects are typically immediate, tolerable, and rapidly reversible. One patient in a clinical study experienced a seizure during the Lobradimil infusion. These side effects are context-dependent and should be considered when designing experiments. For laboratory research use only.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Handling should follow institutional safety protocols.